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The pathophysiology of Helicobacter pylori-associated gas-
troduodenal diseases, ulcerogenesis, and carcinogenesis is inti-
mately linked to activation of epidermal growth factor receptor
(EGFR) and production of vascular endothelial growth factor
(VEGF). Extracellular virulence factors, such asCagA andVacA,
have been proposed to regulate EGFR activation and VEGF pro-
duction in gastric epithelial cells. We demonstrate that the H.
pylori secretory protein, HP0175, by virtue of its ability to bind
TLR4, transactivates EGFR and stimulates EGFR-dependent
VEGF production in the gastric cancer cell line AGS. Knock-out
of the hp0175 gene attenuates the ability of the resultant H.
pylori strain to activate EGFR or to induce VEGF production.
HP0175-induced activation of EGFR is preceded by translo-
cation of TLR4 into lipid rafts. In lipid rafts, the Src kinase
family member Lyn interacts with TLR4, leading to tyrosine
phosphorylation of TLR4. Knockdown of Lyn prevents
HP0175-induced activation of EGFR and VEGF production.
Tyrosine-phosphorylated TLR4 interacts with EGFR. This
interaction is necessary for the activation of EGFR. Disruption
of lipid rafts with methyl -cyclodextrin prevents HP0175-in-
duced tyrosine phosphorylation of TLR4 and activation of
EGFR. This mechanism of transactivation of EGFR is novel and
distinct from that of metalloprotease-dependent shedding of
EGF-like ligands, leading to autocrine activation of EGFR. It
provides new insight into our understanding of the receptor
cross-talk network.
Receptor-tyrosine kinases are among key cell surface recep-
tors that transduce external signals through the membrane to
regulate biological processes, such as cell proliferation, differ-
entiation, and survival. Within this group, the epidermal
growth factor receptor (EGFR)3 family is closely associatedwith
the pathophysiology of cancer. EGFR is mutated or overex-
pressed in a wide variety of epithelial tumors (1–3). The classi-
cal pathway of activation of the EGFR occurs through binding
of a ligand to its extracellular domain and subsequent auto-
phosphorylation of two receptormolecules (4). Ligands such as
epidermal growth factor (EGF) and heparin-binding EGF (HB-
EGF) are synthesized as membrane-spanning molecules that
are proteolytically cleaved to become active. Ligand binding
initiates the formation of activated dimers/oligomers that
undergo autophosphorylation of tyrosine residues in the cyto-
plasmic tail. This serves as the trigger for the recruitment of
adaptor proteins and the initiation of signaling cascades within
the cell.Mutations of EGFR, such as deletion of 801 bp encoded
by exons 2–7 (5), result in a truncated receptor lacking 267
amino acid residues in the extracellular domain. This receptor
shows ligand-independent, constitutive activity associatedwith
increased tumorigenicity of tumors in vivo (6, 7). The paradigm
for transactivation of EGFR has been the G protein-coupled
receptor (GPCR)-mediated pathway (8). GPCR-dependent
activation of matrix metalloproteases leads to cleavage of pro-
HB-EGF and release of the mature growth factor, which then
goes on to activate the EGFR (9–11). Helicobacter pylori is the
causative agent of superficial gastritis, and infection with H.
pylori increases the risk of adenocarcinomaof the stomach (12).
Vascular endothelial growth factor (VEGF) is a key factor
regulating host angiogenesis in H. pylori-linked gastric malig-
nancy (13, 14). However, the underlying mechanisms regulat-
ing the induction of VEGF byH. pylori are incompletely under-
stood. Soluble, secreted factors of H. pylori, such as CagA,
VacA, and BabA, have been reported to elicit a variety of host
molecules involved in remodeling of the gastric epithelium (15).
Signaling through the EGFR family of receptor tyrosine kinases
regulates production of VEGF (16). Reports have documented
the role ofH. pylori in transactivation of the EGFR (17).Herewe
demonstrate an unexpected role of a secretedToll-like receptor
(TLR) 4-interacting protein HP0175 of H. pylori in effecting
TLR4-dependent transactivation of the EGFR, leading to pro-
duction of VEGF. The activation of EGFR does not involve the
classical metalloprotease-dependent transactivation involving
the shedding of HB-EGF or autocrine/paracrine EGF-mediated
activation of EGFR. Our results brings to light a novel element
of the cellular receptor cross-talk network.
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EXPERIMENTAL PROCEDURES
Reagents—Anti-EGFR, anti-phosphotyrosine, and EGF were
from Cell Signaling Technology (Beverly, MA). Antibodies
against Lyn, TLR4, and protein A/G (plus)-agarose, Lyn siRNA,
EGFR siRNA, and control siRNA were from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA); anti-flotillin was from BD
Biosciences; neutralizing TLR4 antibody was from Imgenex
(Bhubaneswar, India); the tyrosine kinase peptide substrate
Raytide, LFM-A13, AG1478, GM6001, NS398, PP2, piceatan-
nol, and protease inhibitors were from EMD Biosciences (San
Diego, CA); and methyl--cyclodextrin (MBCD), luciferin,
anti-FLAG antibody, andM2-FLAG-agarose were from Sigma.
Fugene 6 and anti-Myc antibodies were from Roche Applied
Science, andneutralizing EGFandHB-EGFantibodywere from
R&D Systems (Minneapolis, MN).
Plasmids—TLR4 and its dominant-negativemutant (encoding
amino acids 1–643) lacking the TIR domain have been described
(18).Mutants of hTLR4were generated by site-directedmutagen-
esis based on the principle of overlap extension PCR using pEF-
BOS-TLR4 as template. The first round of PCR was performed
with primer pairs a andb for one reaction andprimer pairs c andd
for the second reaction. The second round of PCR was per-
formed using the products of the first round as templates, and
primers a and d. Primers b and c are depicted in supplemental
Table S1. Primers a and d were 5-GATCTCGAGAAAACCA-
GTGAGGATGATGC-3 and 5-GATGGATCCGATAGAT-
GTTGCTTCCTGCC-3, respectively. The final products were
cloned between the XhoI and BamHI sites of pEF-BOS.
Cell Culture and Infections—The human gastric epithelial
cell line AGS was obtained from the National Centre of Cell
Science (Pune, India) and maintained in Ham’s F-12 medium
supplemented with 10% heat-inactivated fetal bovine serum,
100 units/ml penicillin, and 100 g/ml streptomycin in a
humidified atmosphere containing 5% CO2. Transfections
were routinely carried out using Fugene 6 (Roche Applied Sci-
ence) according to the manufacturer’s protocol. HP0175 was
purified as described earlier (19).
H. pylori strains were grown as described (19) and incubated
with AGS or HEK293 cells at a multiplicity of infection 50–100
on culture plates. Strains 80A and 18A were cag and cag
clinical isolates, respectively, obtained from the National Insti-
tute of Cholera and Enteric Diseases, Kolkata. These strains
have been described previously (20).
VEGF Enzyme-linked Immunosorbent Assay—Cells (0.3 
105/assay) were seeded into 96-well plates. After treatments,
culture supernatants were collected and assayed for VEGF
using theVEGF enzyme-linked immunosorbent assay kit (R&D
Systems) according to the manufacturer’s instructions.
Reverse Transcription-PCR—Total RNA was prepared from
AGS cells using the RNeasy Mini kit (Qiagen) according to the
manufacturer’s protocol. A total of 100 ng of RNA was reverse
transcribed using the Titanium One-Step reverse transcrip-
tion-PCR kit (BDBiosciences). The primers 5-CTGCTGTCT-
TGGGTGCATTG-3 (sense) and 5-TTCACATTTGTTGT-
GCTGTAG-3 (antisense) were used to amplify 378 bp of vegf
mRNA. Glyceraldehyde-3-phosphate dehydrogenase was
amplified using the primers 5-CCATCAATGACCCCTTCA
TTG ACC-3 (sense) and 5-GAA GGC CAT GCC AGT GAG
CTTCC-3 (antisense) to generate a 604-bp product. The PCR
conditions for vegf mRNA were denaturation at 94 °C for 30 s,
annealing at 56 °C for 1min, and extension at 68 °C for 1min for
30 cycles.
Luciferase Reporter Assay—The vegf promoter (2018 to
50) was amplified by PCR using the primer pair 5-ATAGG-
TACCTCTACAGCTTGTGCTCCT-3 (sense), and 5-ATA-
AAGCTTCCCCCAGCGCCACGACCT-3 (antisense). The
product was cloned into the vector pGL2 Basic (Promega) har-
boring the promoterless luciferase gene, using asymmetric
KpnI and HindIII sites (underlined). AGS cells (2 105/assay)
were transfected with the luciferase reporter construct along
with -galactosidase construct using Fugene 6. Transfected
cells after treatment were lysed in buffer containing 25 mM
Tris-HCl, pH 7.8, 2 mM dithiothreitol, 1% Triton X-100, 4 mM
EGTA, 10% glycerol, 20 g/ml aprotinin, 10 g/ml pepstatin,
and 10 g/ml leupeptin and centrifuged, and the supernatant
was assayed for luciferase activity using luciferin as substrate.
EGFR and Lyn Kinase Assays—Cells after treatment were
lysed in buffer containing 50mMHEPES, pH 7.2, 150mMNaCl,
1 mM EDTA, 1 mM sodium orthovanadate, 1% (v/v) Triton
X-100, 10% glycerol, 40 mM sodium -glycerophosphate, 20
mMNaF, 10mM sodiumpyrophosphate, 10g/ml leupeptin, 10
g/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride
(buffer A). Lysates were clarified by centrifugation. For EGFR
kinase assays, EGFR was immunoprecipitated with anti-EGFR
antibody. Immunoprecipitates were washed three times with
buffer A and twice with kinase buffer (20 mMHEPES, pH 7.2, 3
mM NaCl, 2 mM MnCl2, 24 M EDTA, 50 M sodium
orthovanadate, 0.15 M -mercaptoethanol). Beads were
resuspended in 50 l of kinase buffer containing 100 ng of the
synthetic peptide RLIEDNEYTARG (sc-3049; Santa Cruz Bio-
technology), and 20 M [-32P]ATP (20 Ci/mmol). After incu-
bation at 30 °C for 30 min, the incorporation of phosphates in
the peptide was determined by spotting on p81 phosphocellu-
lose paper. Lyn kinase assays were similarly performed using
the peptide substrate Raytide.
Study of the Interaction of TLR4 with EGFR—Cells were
transfected with FLAG-TLR4 (or its mutants). After treat-
ments, cells were lysed in buffer A, followed by clarification of
the supernatant by centrifugation and incubation with anti-
FLAG antibody (1:100) overnight at 4 °C. Protein A-agarose
was subsequently added and kept for another 3 h. Immunopre-
cipitated proteins were boiled in Laemmli buffer, separated by
SDS-PAGE, and immunoblotted with anti-EGFR antibody to
detect coimmunoprecipitated EGFR.
Analysis of Tyrosine Phosphorylation of TLR4—AGS cells
were transfected with FLAG-TLR4 constructs as described
above. After treatments, cells were lysed, immunoprecipitated
with anti-FLAG antibody, and immunoblotted using anti-
phosphotyrosine antibody.
Transfection of Small Interfering RNAs (siRNAs)—Cells were
transfected with EGFR or Lyn or control siRNA (Santa Cruz
Biotechnology) according to the manufacturer’s protocol.
Silencing of either EGFR or Lyn kinase was confirmed byWest-
ern blotting of cell lysates with anti-EGFR or anti-Lyn antibody.
TLR4-dependent EGFR Transactivation
32370 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 47•NOVEMBER 21, 2008
 by guest, on August 31, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2008/09/22/M805053200.DC1.html
Supplemental Material can be found at:
Isolation of LipidRafts andWesternAnalysis—AGScells (2
106/assay) after treatment were lysed at 4 °C in 1.5 ml of TBS
containing 1% Triton X-100, protease inhibitors, and 1 mM
EDTA and subjected to a sucrose flotation gradient. After 30
min at 4 °C, the extract was mixed with an equal volume of 80%
(w/v) sucrose, overlaid with 30% (w/v) sucrose and 5% sucrose,
and subjected to ultracentrifugation in an AH-629 rotor (Sor-
vall) at 27,000 rpm for 3 h at 4 °C. Fractions were collected as
described (21), immunoprecipitated with 1 g of anti-EGFR or
anti-TLR4 or anti-flotillin antibody, boiled in Laemmli buffer,
and subjected to analysis by Western blotting using the same
antibodies.
RESULTS
HP0175 Induces VEGF Production in Gastric Epithelial Cells—
In our effort to define in detail the repertoire of molecules
responsible for VEGF expression, we tested the effect of
HP0175, a soluble TLR4-interacting protein previously charac-
terized by us (19). Unless stated otherwise, recombinant
HP0175 purified from Escherichia coli was used for all studies.
Herewe show that exogenousHP0175 stimulates VEGF release
from AGS cells. The HP0175-induced release of VEGF was
time- and concentration-dependent (Fig. 1, A and B). Recom-
binant HP0175 purified fromHEK293 cells also induced VEGF
production (Fig. 1B, last bar), ruling out the possibility that
endotoxin contamination was responsible for the observed
effect of the recombinant protein. VacA has been identified as
one of the soluble factors of H. pylori responsible for VEGF
release from epithelial cells (13). HP0175-mediated release of
VEGF was comparable with that elicited by VacA (data not
shown). The role of HP0175 was supported by the observation
that an isogenic strain inactivated in hp0175 showed signifi-
cantly reduced VEGF-inducing ability, which was restored
upon complementation with the hp0175 gene (Fig. 1C).
HP0175 induced vegf transcription and activated VEGF pro-
moter-driven luciferase expression in a time-dependent man-
ner (supplemental Fig. S1, A and B, respectively). VEGF pro-
moter-driven luciferase expression was diminished in amutant
inactivated in hp0175 (Fig. 1D) and restored upon complemen-
tation with hp0175, supporting the notion that HP0175 is an
important bacterial factor that elicits vegfproduction inH. pylo-
ri-challenged gastric epithelial cells.
HP0175-mediated VEGF Production Is Dependent on TLR4
and EGFR—We next attempted to delineate the signaling
events associated with exogenous HP0175-mediated produc-
tion of VEGF. Taking into account the fact that HP0175 inter-
acts with TLR4, we tested the role of TLR4 in HP0175-depend-
ent VEGF production. Treatment of AGS cells with
neutralizing antibodies against TLR4 inhibited HP0175-in-
duced VEGF release (Fig. 1E). However, VacA-mediated VEGF
release from AGS cells occurred in a TLR4-independent man-
ner (data not shown). Cells transfected with dominant negative
TLR4 also showed attenuation of HP0175-induced vegf pro-
moter-driven luciferase expression (Fig. 1F). This suggested a
role of TLR4 inVEGFproduction in this instance. In view of the
fact that VEGF production is associated with activation of
EGFR (13), we tested the possible involvement of EGFR in
HP0175-induced VEGF production. Knockdown of EGFR by
RNA interference (supplemental Fig. S1C) attenuatedHP0175-
driven VEGF production (Fig. 1G) and VEGF promoter-driven
luciferase activation (Fig. 1H).
HP0175 Activates EGFR in aMetalloproteinase-independent
Manner—The observation that both TLR4 and EGFR were
involved in HP0175-driven VEGF production, provided the
motivation to test the possibility that cross-talk between TLR4
and EGFR leads to activation of EGFR. This is the focus of the
present report. Considering that HP0175-mediated VEGF pro-
ductionwas dependent on EGFR, we testedwhether exogenous
HP0175 activates EGFR in AGS cells. HP0175 activated EGFR
in a time- and dose-dependent manner (Fig. 2, A and B). Acti-
vation of EGFR was inhibited by the EGFR inhibitor AG1478
FIGURE 1.HP0175 stimulates VEGF production in AGS cells. Cells were left
untreated (none) or treated with HP0175 (1 g/ml) for different periods of
time (A) or for 24 h with different concentrations of HP0175 (B) purified from
E. coli (A and B) or from HEK 293 cells (B, last bar). In separate sets of experi-
ments, cellswereeitherpretreatedwithneutralizingantibodyagainst TLR4or
isotype IgG (E) or transfected with control or EGFR-specific siRNA (G). C, cells
were treated with wild type H. pylori or the hp0175-inactivated mutant
(knock-out; KO) or knock-out complemented with hp0175 (com.) for 24 h. In
A–C, E, andG, the release of VEGFwasmeasured in the supernatant using the
VEGF enzyme-linked immunosorbent assay kit according to themanufactur-
er’s protocol. D, in order to measure vegf promoter activation, cells were
transfected with vegf promoter luciferase reporter and -galactosidase con-
struct before incubation with wild type H. pylori or the hp0175-inactivated
mutant (KO) or knock-out complemented with hp0175 (com.). F, in separate
experiments, cells were transfected either with empty vector or with domi-
nant-negative TLR4 (TLR4(dn)) along with vegf promoter luciferase reporter
and-galactosidase construct followedby incubationwithout () orwith ()
HP0175 (1g/ml) for 5 h.H, cells were transfectedwith control or EGFR siRNA
prior to transfection with vegf promoter luciferase reporter construct and
treatment as described for F. In D, F, and H, luciferase was measured as
described under “Experimental Procedures.” Results represent the means
S.D. of three separate experiments.
TLR4-dependent EGFR Transactivation
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(Fig. 2B).HP0175purified fromHEK293cells alsoactivatedEGFR
(Fig. 2A). A previous report (17) has suggested that shedding of
HB-EGF by the action of matrix metalloproteinases is linked to
H. pylori-mediated activation of EGFR. We therefore tested
whether HP0175 was activating such a pathway. Neither neutral-
izingHB-EGF antibody (Fig. 2A) norGM6001 (batimastat, amet-
alloproteinase inhibitor) (Fig. 2B) inhibitedHP0175-driven activa-
tion of EGFR. As a control, neutralizing HB-EGF antibody was
capable of inhibiting HB-EGF-elicited EGFR kinase activity (sup-
plemental Fig. S1D). As expected, HP0175-induced VEGF pro-
ductionwas alsonot inhibited (data not shown).NeutralizingEGF
antibody did not inhibit HP0175-induced VEGF release, whereas
EGF-induced VEGF release was inhibited by this antibody (sup-
plemental Fig. S1E). This suggested the likelihood of HP0175
inducing a novel transactivation mechanism. The ability of the
intact bacterium to activate EGFR was diminished in a mutant
inactivated in hp0175 (supplemental Fig. S1F) and restored upon
complementation with hp0175. EGFR kinase activation by
H.pyloriwas abrogatedwhenAGScellswere pretreatedwithneu-
tralizing TLR4 antibody but not when cells were pretreated with
neutralizing HB-EGF antibody or with GM6001 (supplemental
Fig. S1F). These results provided support to the view that TLR4-
dependent transactivation of EGFR plays an important role in
H. pylori-induced signaling in gastric epithelial cells.
HP0175 Drives the Interaction between TLR4 and EGFR and
Activation of EGFR—Co-immunoprecipitation studies were
performed to determine whether HP0175 treatment of AGS
cells triggered interaction of EGFR
with TLR4. EGFR was detected
in lysates of HP0175-stimulated
FLAG-TLR4-transfected AGS cells
captured with FLAG antibody but
not in control lysates (Fig. 2C) or in
cells stimulated with an irrelevant
His-tagged protein (data not
shown). HP0175 expressed in
HEK293 cells was also found to
stimulate the interaction of TLR4
with EGFR (data not shown).
HEK293 cells are naturally TLR4-
and TLR2-negative. Expression of
TLR4 led to activation of EGFR
kinase in a time-dependent manner
in response to challenge with
HP1075 (Fig. 2D). TLR2-trans-
fected HEK293 cells did not show
EGFR kinase activation in response
to HP0175 (Fig. 2D), indicating the
specificity of the observed effects.
Lipopolysaccharide, a TLR4 ligand,
was unable to induce EGFR kinase
activity or VEGF release from AGS
cells (Fig. 2A, last bar), indicating
that the effect was specific for
HP0175.
HP0175 Signaling Triggers Acti-
vation of Lyn Kinase—Activation
of EGFR involves Src-dependent
phosphorylation of EGFR (4). Among the members of the Src
family, AGS cells express c-Src and Lyn (22). We evaluated the
role of Src family kinases in HP0175-driven signaling events by
measuring HP0175-mediated VEGF release and EGFR kinase
activation. Both VEGF promoter-driven luciferase activation
(supplemental Fig. S1B) and EGFR kinase activation (Fig. 3A)
were inhibited by pretreatment with the Src family kinase
inhibitor, PP2. Knockdown of Lyn kinase by RNA interference
(supplemental Fig. S1G), inhibited HP0175-induced VEGF
promoter-driven luciferase (Fig. 3B) as well as EGFR activation
(Fig. 3C). HP0175-driven phosphorylation of Lyn on tyrosine
residues occurred in a time-dependentmanner (Fig. 3D). How-
ever, Lyn kinase was not affected by knockdown of EGFR (sup-
plemental Fig. S2A). HP0175-induced Lyn kinase activity and
tyrosine phosphorylation of Lyn were inhibited in AGS cells
transfected with dominant negative TLR4 (Fig. 3, E and F,
respectively) and Lyn kinase activity was inhibited in cells pre-
treated with neutralizing antibodies against TLR4 (supplemen-
tal Fig. S2B), arguing in favor of an essential role of TLR4 in Lyn
activation. It therefore appeared that the binding of HP0175 to
TLR4 facilitates binding of Lyn to its intracellular domain and
subsequent activation of Lyn. In monocytic cells, the tyrosine
kinase Syk has been reported to associate with TLR4 (23). We
did not observe association of Syk with TLR4 after treatment of
AGS cells with HP0175 (data not shown). The ability of the
intact bacterium to activate Lyn kinase was diminished in a
FIGURE 2.HP0175-stimulated EGFR kinase activity and interaction of EGFRwith TLR4. Cells were treated
with HP0175 (1 g/ml) for different periods of time (A) or at different concentrations for 3 h (B). Where indi-
cated, cells were treated either with neutralizing anti-HB-EGF (A) or with different inhibitors (B) prior to treat-
mentwithHP0175. InA, cells were also treated separatelywithHP0175 (1g/ml) purified fromHEK 293 cells or
with lipopolysaccharide (1g/ml) for 3 h. In all cases, cells were lysed and immunoprecipitatedwith anti-EGFR
antibody, and kinase activitywasmeasured as described under “Experimental Procedures.”C, in order to study
the interaction of EGFR with TLR4, cells were transfected with FLAG-tagged TLR4 (wild type (WT)) or the
indicated mutants and treated without () or with () HP0175 (1 g/ml) for 60 min. Cells were lysed and
immunoprecipitated with M2-FLAG-agarose, followed by Western blotting with anti-EGFR antibody. The blot
was reprobedwith anti-FLAG antibody.D, HEK 293 cells (in 24-well plates) were transfected eitherwith TLR4 or
TLR2 as indicated. Cells were treated with HP0175 (1 g/ml), and EGFR kinase activity was measured as
described for A. Results in A, B, and D represent the means S.D. of three separate experiments. The blot in C
is a representative of three separate experiments.
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mutant inactivated in hp0175 and restored upon complemen-
tation with hp0175 (supplemental Fig. S3A).
LynKinase Phosphorylates TLR4—TLR4 phosphorylation on
tyrosine residues has been reported to be involved in TLR4-de-
pendent signaling events (24).HP0175 inducedTLR4phospho-
rylation on tyrosine residues in a time-dependent manner (Fig.
4A). The Src kinase inhibitor PP2 inhibited tyrosine phospho-
rylation of TLR4 in HP0175-treated cells in a dose-dependent
manner (Fig. 4A). Knocking down of Lyn using Lyn-specific
siRNA abrogated the tyrosine phosphorylation of TLR4 (Fig.
4B) and its interactionwith EGFR (supplemental Fig. S3B). Pre-
treatment of cells with piceatannol, an inhibitor of Syk kinase or
with LFM-A13, an inhibitor of Bruton’s tyrosine kinase, did not
affect tyrosine phosphorylation of TLR4 (data not shown). Nei-
ther LFM-A13 nor piceatannol affected HP0175-induced
EGFR kinase activation (Fig. 2B). Tyr674 and Tyr680 have been
identified as phosphorylatable tyrosine residues of TLR4 (24),
whereas Pro714 is crucial for signaling downstream of TLR4.
Mutation of either Tyr674 or Tyr680 or both led to partial inhi-
bition of HP0175-dependent tyrosine phosphorylation of
TLR4, whereas the P714A mutation showed complete inhibi-
tion of TLR4 phosphorylation on tyrosine residues (Fig. 4C).
These results suggested that as in the case of lipopolysaccharide
signaling, these residues were probably important in HP0175-
mediated signaling events. The role of HP0175 in mediating
H. pylori-induced TLR4 tyrosine phosphorylation was con-
firmed by challenging AGS cells with bacteria inactivated in
hp0175. Tyrosine phosphorylation of TLR4 and its interaction
with EGFRwere abrogated in the knock-out strain but restored
upon complementation with hp0175 (supplemental Fig. S4, A
andC). Although HP0175 induced tyrosine phosphorylation of
TLR4 in AGS cells, VacA, which like HP0175, elicits VEGF
release, did not do so (supplemental Fig. S4B). We tested inter-
action of TLR4 with Lyn in response to treatment of AGS cells
transfected with different FLAG-tagged constructs of TLR4.
Lyn could be coimmunoprecipitated with TLR4 (Fig. 4D). This
interaction was not affected in cells transfected with tyrosine
phosphorylation-defective mutants of TLR4 (Fig. 4D), suggest-
ing that tyrosine phosphorylation of TLR4 is not necessary for
its interaction with Lyn.
Phosphorylation of TLR4 Is Required for EGFR Trans-
activation—In order to explore the role of tyrosine phosphoryl-
ation of TLR4 in its interaction with EGFR, AGS cells were
transfected with FLAG-tagged TLR4 (P714A) (which is defec-
tive in tyrosine phosphorylation), challenged with HP0175, fol-
lowed by immunoprecipitation with anti-FLAG and probing of
the immunoprecipitates with anti-EGFR antibody. Interaction
FIGURE 3. HP0175 activates Lyn kinase. A, AGS cells were left untreated or
were pretreated with the Src kinase inhibitor PP2 for 30 min, followed by
incubationwithout () or with () HP0175 for 3 h andmeasurement of EGFR
kinase activity. Cells were transfected with either control (con.) or with Lyn-
specific (lyn) siRNA and treated without or with HP0175, followed by meas-
urement of VEGF luciferase (B) or EGFR kinase (C) activity. D, AGS cells were
treatedwith HP0175 for different periods of time, lysed, and immunoprecipi-
tated with anti-Lyn antibody, followed by Western blotting with anti-phos-
photyrosine antibody. E, cells were transfected eitherwith empty vector (vec)
or TLR4 (dn), followed by incubationwithout or with HP0175 for 40min. Cells
were lysed and immunoprecipitated with anti-Lyn antibody, and the immu-
noprecipitate was used to measure Lyn kinase activity, as described under
“Experimental Procedures.” F, lysates were prepared from transfected cells
treatedwithHP0175 (as in E) for different periods of timeand immunoblotted
with anti-phosphotyrosine antibody. Blots were reprobedwith anti-Lyn anti-
body to ensure equal loading in all lanes. Results in A–C and E represent the
means S.D. of three separate experiments. Blots are representative of three
separate experiments. HP0175 was used at a concentration of 1 g/ml.
FIGURE 4. HP0175 activates Lyn-mediated TLR4 phosphorylation and
EGFR kinase. A, AGS cells were transfectedwith wild type (WT) FLAG-tagged
TLR4 or its mutants as indicated (A–E). A, cells transfectedwithWT-TLR4were
left untreated or treated with PP2 at different concentrations, followed by
treatment without () or with () HP0175 for the indicated time periods (A)
or for 40min (C–E). B, cells were transfectedwith either control siRNA (con.) or
Lyn siRNA (lyn), followed by treatment without () or with () HP0175. Cells
were lysed after treatments. For A–D, lysates were immunoprecipitated with
M2 FLAG-agarose, and Western blotting was performed with anti-phospho-
tyrosine antibody (A–C) or with anti-Lyn antibody (D). Blots were reprobed
with anti-FLAG antibody to ensure equal loading. E, EGFR kinase activity was
measured as described in the legend to Fig. 2A. Results in E represent the
means S.D. of three separate experiments. Blots are representative of three
separate experiments. HP0175 was used at a concentration of 1 g/ml.
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ofTLR4with EGFRwas compromised in theTyr674 orTyr680 or
the Tyr674/Tyr680 mutants. On the other hand, it was negligible
for the P714A mutant (Fig. 2C). Tyrosine phosphorylation of
TLR4 therefore appeared to be a prerequisite for its interaction
with EGFR. Consistent with these observations, EGFR kinase
activity was attenuated in cells transfected with the aforesaid
mutant of TLR4 (Fig. 4E) as well as after knockdown of Lyn
kinase by RNA interference (supplemental Fig. S1H).
HP0175 Induces Translocation of TLR4 into Rafts—Translo-
cation of signaling receptors to lipid rafts is a well documented
event governing spatiotemporal control of signaling events
(25). Pretreatment of AGS cells with MBCD, which specifically
depletes cholesterol and disrupts lipid raft organization, led to
an abrogation of HP0175-induced VEGF promoter-driven
luciferase production (supplemental Fig. S1B), suggesting a role
of lipid rafts in the signaling events triggered by HP0175. We
observed that a fraction of EGFR is constitutively present in
lipid rafts of AGS cells (Fig. 5A), an observation made in Chi-
nese hamster ovary cells as well (26). On the other hand, TLR4
translocated into rafts in a time-dependent manner after chal-
lenge withHP0175 (Fig. 5A) andwas observed in rafts up to 120
min. Pretreatment of cells withMBCDprevented the activation
of EGFR and Lyn kinases (Fig. 5,B andC, respectively) as well as
the tyrosine phosphorylation of TLR4 (Fig. 5D), supporting the
contention that Lyn-mediated tyrosine phosphorylation of
TLR4 requires the presence of TLR4 in lipid rafts.
DISCUSSION
H. pylori ranks among the most successful microbes to have
colonized the human stomach (27–29). Only a proportion of
infected individuals develop ulcers, gastric adenocarcinoma, or
gastric lymphoma (27, 30). Due to its role as an angiogenic
factor, VEGF plays an important role in H. pylori-associated
gastroduodenal diseases (31). VEGF is overexpressed in human
gastric adenocarcinomas (32). On the one hand, it is involved in
the reconstruction of normal mucosal architecture required
during healing. On the other hand, VEGF also promotes gastric
carcinomas by supporting tumor-associated angiogenesis.
Considering the importance of VEGF, we initiated studies to
determine whether the TLR4-interacting, secreted antigen
HP0175 previously characterized by us (19) is involved inmod-
ulating VEGF production in gastric epithelial cells.
We observed that HP0175 elicited VEGF release in a TLR4-
dependent manner. Elevated expression of TLR4 has been
reported in gastric biopsy samples associated with H. pylori
infection compared with uninfected samples (33), suggesting a
probable involvement of TLR4 in H. pylori-associated patho-
physiology. It was therefore of obvious relevance to understand
the mechanism of HP0175-induced TLR4-dependent VEGF
release. In view of the reports of involvement of EGFR in VEGF
production (34, 35), here we focused our attention on under-
standing whether EGFR was involved in VEGF release and
whether cross-talk between TLR4 and EGFR could be the trig-
ger for HP0175-mediated VEGF production. RNA interference
knockdown of EGFR supported the view that EGFR was
involved in HP0175-mediated VEGF production. Most inter-
estingly, we observed that exogenous HP0175 was capable of
triggering EGFR activation. Intestinal homeostasis has been
reported to be associated with TLR4-dependent up-regulation
of cyclooxygenase-2 (36). Our results using the cyclooxygen-
ase-2 inhibitor NS398 ruled out the involvement of cyclooxy-
genase-2 in HP0175-dependent EGFR kinase activation (Fig.
2B). Using intact bacteria, we also demonstrate that TLR4-de-
pendent EGFR activation occurs irrespective of the status of the
cag pathogenicity island (supplemental Fig. S1I). This contra-
dicts the observations of Keates et al. (37), who have reported
that infection of AGS cells byH. pylori is associated with EGFR
transactivation andup-regulation of EGFR expression, an effect
limited to cag strains. According to Keates et al. (17),H. pylori-
mediated EGFR activation is dependent on shedding of HB-
EGF, an observation that does not agreewith the findings of this
study. In this connection, it is to be pointed out that Keates et al.
have demonstrated phosphorylation of EGFR on tyrosine resi-
dues as the only evidence of EGFR transactivation, unlike in our
study, where the kinase activity of EGFR has been measured.
Several mechanisms of transactivation of EGFR have been
reported. The GPCR protease-activated receptor-2 is capable
of transactivating EGFR in the gastric cancer cell lines AGS and
MKN28 (38). Thismechanism is dependent on the activation of
Src and is brought about by the action of EGF-like ligands that
are cleaved and released bymatrixmetalloproteinases. Another
GPCR, platelet-activating factor receptor, is involved in bacte-
FIGURE 5. Involvement of lipid rafts in HP0175-mediated signaling in
AGS.A, cells grownon35-mm tissue culture plateswere treatedwithHP0175
(1 g/ml) for different periods of time (as indicated) and lysed. The Triton
X-100 extract was fractionated by density gradient centrifugation as
described under “Experimental Procedures,” and fractions were immuno-
blotted with anti-TLR4 or anti-EGFR or anti-flotillin (raft marker) antibody.
B and C, AGS cells were left untreated or pretreated with either MBCD or
vehicle followed by incubation without (control) or with HP0175. Cell lysates
were used to measure EGFR (B) or Lyn (C) kinase activity, as described under
“Experimental Procedures.” D, cells were transfected with FLAG-TLR4, fol-
lowed by pretreatment with vehicle or MBCD. Cells were incubated without
() or with () HP0175, lysed, immunoprecipitated with M2-FLAG-agarose,
and immunoblotted with phosphotyrosine antibody. HP0175 was used at a
concentration of 1 g/ml.
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rial lipoteichoic acid-mediated activation of EGFR, again
involving a metalloprotease, ADAM10 (39). Several other
reports have also demonstrated that activation of metallopro-
teases cleaves ligands involved in autocrine stimulation of
EGFR (40, 41). Using an inhibitor of matrixmetalloproteinases,
we do not find evidence of involvement of matrix metallopro-
teinase(s) in HP0175-mediated activation of EGFR. In A431
carcinoma cells, HSP70-mediated association of TLR4 with
EGFR and subsequent activation of EGFR was reported (42),
although a detailed mechanism was not explored. Our report
brings to light an unexpected novel mechanism of EGFR acti-
vation discussed below.
Sucrose density gradient centrifugation provides evidence
for the localization of TLR4 with the lipid raft marker flotillin,
suggesting that the binding of HP0175 to TLR4 triggers the
translocation of TLR4 to lipid rafts (supplemental Fig. S5). This
is a step that we recognize as a prerequisite for EGFR activation,
since MBCD prevents activation of EGFR. Among eight mem-
bers of the Src kinase family tested, AGS cells have been
reported to express c-Src, Lyn, and c-Fgr (22).We further dem-
onstrate that the translocation of TLR4 to lipid rafts facilitates
its interaction with Lyn, followed by Lyn-dependent phospho-
rylation of TLR4 on tyrosine residues. Mutants of TLR4 inca-
pable of undergoing Lyn-dependent phosphorylation on
tyrosines could bind to Lyn but failed to activate EGFR. The
detailed mechanism of TLR4-dependent EGFR activation
requires further exploration. In light of the report by Evdonin
et al. (42), it would be interesting to test whether the tyrosine
phosphorylation of TLR4 is also required for TLR4-dependent
EGFR activation in A431. A clinical isolate lacking the com-
plete cag pathogenicity island is still capable of activating
EGFR (supplemental Fig. S1I). In addition, pretreatment
with neutralizing antibodies against TLR4 abrogates EGFR
activation by H. pylori irrespective of the status of the cag
pathogenicity island (data not shown). These results provide
the basis of our contention that TLR4-dependent transacti-
vation of EGFR induced by HP0175 probably plays a role in
the pathophysiology of ulcerogenesis and/or carcinogenesis.
Disruption of epithelial tight junctions by the interaction of
translocated CagA with the scaffolding protein Zo-1 (43) and
VacA-mediated phosphorylation of GPCR kinase interactor 1
(44) could facilitate binding of EGF ligands to the EGFR. Over-
expression of metalloproteases involved in ectodomain shed-
ding of membrane proteins has been reported in the gastric
mucosa of H. pylori-infected patients (45) This suggests that
ADAM-dependent transactivation of the EGFR is likely to be of
pathophysiological relevance. However, our findings suggest
that H. pylori has multiple mechanisms of transactivating the
EGFR. These findings are of importance in the context of
enriching our understanding of cross-talk between EGFR and
other cell surface receptors. Our previous studies had indicated
thatHP0175 induces apoptosis in AGS cells (19). It is intriguing
that the same protein also triggers release of the angiogenic
factor VEGF. Our preliminary, unpublished observations4 sug-
gest that HP0175 triggers both HIF-1 (which promotes VEGF
production) and p53 (which is proapoptotic), with different
time kinetics of induction of the two proteins. The temporal
course of synthesis and turnover of these two proteins probably
decides the outcome on system behavior. These processes are
being investigated in detail now.The observationsmade in vitro
on AGS, a gastric cancer-derived epithelial cell line underscore
the importance of pursuing further experimentation in vivo on
the role of the described signaling pathway in ulcerogenesis
and/or carcinogenesis.
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